 Patent Application Title |
Patent App Num. |
Date |
| Ketorolac tromethamine compositions for treating or preventing ocular pain | 20110021595 | 20110127 |
| The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises mixtures of carboxymethyl cellulose in an aqueous solution wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye and improve visual acuity of the users.
... |
| Prevention of acute kidney injury | 20100266712 | 20101021 |
| The present invention provides a method of attenuating or preventing acute kidney injury occurring in a subject following cardiac surgery involving cardio-pulmonary bypass. The method comprises administration of at least one agent which cause alkalinization of urine to the subject at a level effective to cause alkalinization of the subject's urine. Preferably the agent which cause alkalinization of urine is selected from the group consisting of sodium bicarbonate, lactate, acetate, citrate, tromethamine and combinations thereof and is most preferably sodium bicarbonate.
... |
| Ketorolac tromethamine compositions for treating or preventing ocular pain | 20100087503 | 20100408 |
| The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution which provides increased visual acuity in users and wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient which is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.
... |
| Salts with crth2 antagonist activity | 20100056544 | 20100304 |
| The potassium, sodium, ammonium, lysine, diethylamine, tromethamine (TRIS), piperazine, ethylenediamine and ethanolamine salt of a compound of general formula (I): wherein R1 is halo or cyano; R2 is C1-C4 alkyl; and R3 is quinolyl or phenyl substituted with methane sulfonyl; can be synthesised by a novel method and are substantially more soluble than the parent free acids in a range of solvents.
... |
| Prevention of acute kidney injury | 20100266712 | 20101021 |
| The present invention provides a method of attenuating or preventing acute kidney injury occurring in a subject following cardiac surgery involving cardio-pulmonary bypass. The method comprises administration of at least one agent which cause alkalinization of urine to the subject at a level effective to cause alkalinization of the subject's urine. Preferably the agent which cause alkalinization of urine is selected from the group consisting of sodium bicarbonate, lactate, acetate, citrate, tromethamine and combinations thereof and is most preferably sodium bicarbonate.
... |
Subscribe to updates on this page: Tromethamine RSS  |
| Ketorolac tromethamine compositions for treating or preventing ocular pain | 20100087503 | 20100408 |
| The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution which provides increased visual acuity in users and wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient which is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.
... |
| Salts with crth2 antagonist activity | 20100056544 | 20100304 |
| The potassium, sodium, ammonium, lysine, diethylamine, tromethamine (TRIS), piperazine, ethylenediamine and ethanolamine salt of a compound of general formula (I): wherein R1 is halo or cyano; R2 is C1-C4 alkyl; and R3 is quinolyl or phenyl substituted with methane sulfonyl; can be synthesised by a novel method and are substantially more soluble than the parent free acids in a range of solvents.
... |
| Ketorolac tromethamine compositions for treating or preventing ocular pain | 20090326034 | 20091231 |
| The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.
... |
| Pharmaceutical oral dosage form comprising a non-steroidal anti-inflammatory drug, and having good palatability | 20080292606 | 20081127 |
| Oral pharmaceutical dosage form comprising tromethamine and a NSAID selected from the group comprising ibuprofen, naproxen and flurbiprofen, characterized in that it also comprises a compound selected from the group comprising glycine, vitamin B6 and mixtures thereof.
... |
| Stable oral pharmaceutical composition | 20080182887 | 20080731 |
| The invention relates to a stable oral pharmaceutical composition comprising atorvastatin or its pharmaceutically acceptable salt and a pharmaceutically acceptable carrier comprising tromethamine and an antioxidant.
... |
| Ketorolac tromethamine compositions for treating or preventing ocular pain | 20080027120 | 20080131 |
| Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.
... |
| Continuous cardiac perfusion preservation with peg-hb for improved hypothermic storage | 20070243518 | 20071018 |
| Efforts to extend myocardial preservation for transplantation by perfusion with prior crystalloid based solutions have been limited by edema and compromised function. Hypothermic perfusion preservation with a polyethylene glycol (PEG) conjugated hemoglobin solution extends preservation times. The polyethylene glycol (PEG) conjugated hemoglobin solution comprises PEG-Hb, and at least one of the constituents selected from the group of human albumin, dextrose, heparin sodium, lidocaine HCl, MgSO4, KCl, CaCl2, Tromethamine (THAM) solution, NaCl, NaHCO3, and Na2HPO4/NaH2PO4. Comparison of cardiac function after continuous perfusion using a hypocalcemic normokalemic crystalloid perfusate is made with and without the addition of PEG-Hemoglobin (Hb).
... |
| Stable parenteral formulation of fosphenytoin sodium | 20070244074 | 20071018 |
| A more stable formulation of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester, wherein the composition is made more stable by using a solution essentially free of tromethamine.
... |
Subscribe to updates on this page: Tromethamine RSS |
